# TLSA catalysts: Tiziana Life Sciences Ltd PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tlsa/catalysts

> Tiziana Life Sciences Ltd (TLSA) has 5 upcoming catalysts. The next is the foralumab topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, year only, half-year only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for TLSA?

Tiziana Life Sciences Ltd (TLSA) has 5 upcoming catalysts. The next is the foralumab topline data readout, Q1 2027. Press release filed with the SEC (EX-99): "Topline data are anticipated to be announced in Q1 2027." [Calendar and source filings](https://sec-api.dev/companies/tlsa/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001213900-26-110008, https://www.sec.gov/Archives/edgar/data/1723069/000121390026110008/ea030884501ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-10-16. Cite: https://sec-api.dev/companies/tlsa/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Tiziana Life Sciences Ltd |
| Ticker | TLSA (Nasdaq) |
| SEC CIK | 1723069 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/tlsa |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 19, 2023 | [Foralumab trial start](https://sec-api.dev/pdufa/foralumab) | TLSA | non-active SPMS | completed | "December 19, 2023, we announced "first patient dosed" in our Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active SPMS." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1723069/000121390026006375/ea0273606-424b5_tiziana.htm)) |
| February 11, 2025 | [Foralumab trial start](https://sec-api.dev/pdufa/foralumab) | TLSA |  | completed | "Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390025011952/ea023065001ex99-1_tiziana.htm)) |
| April 23, 2025 | [Foralumab trial start](https://sec-api.dev/pdufa/foralumab) | TLSA | non-active secondary progressive multiple sclerosis | completed | "TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosis (na-SPMS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390025034332/ea023921901ex99-1_tiziana.htm)) |
| Q4 2025 | [Foralumab topline data readout](https://sec-api.dev/pdufa/foralumab) | TLSA |  | scheduled | "Topline results are anticipated by Q4 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1723069/000121390025040218/ea0239559-20f_tiziana.htm)) |
| December 17, 2025 | [Foralumab trial start](https://sec-api.dev/pdufa/foralumab) | TLSA | early Alzheimer's disease | completed | "Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer's disease (AD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390025122553/ea027004801ex99-1_tiziana.htm)) |
| 2026 | [Foralumab interim data readout](https://sec-api.dev/pdufa/foralumab) | TLSA |  | scheduled | "Interim data are anticipated in 2026, with results intended to guide future development and potentially establish neuroimmune modulation as a key pillar in AD therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390025122553/ea027004801ex99-1_tiziana.htm)) |
| 1H 2026 | [Foralumab topline data readout](https://sec-api.dev/pdufa/foralumab) | TLSA |  | scheduled | "Tiziana is advancing intranasal foralumab in an ongoing randomized, double-blind, placebo-controlled Phase 2a trial (NCT06292923) in na-SPMS, with top-line data expected in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390026020114/ea027831601ex99-1.htm)) |
| April 2026 | [Foralumab tzls-401 100 µg primary completion](https://sec-api.dev/pdufa/foralumab-tzls-401) | TLSA | Non-Active Secondary Progressive Multiple Sclerosis | delayed | "NCT06890923 (Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-04-30 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890923)) |
| September 17, 2026 | [Foralumab primary completion](https://sec-api.dev/pdufa/foralumab) | TLSA | Secondary Progressive Multiple Sclerosis | completed | "NCT06292923 (A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06292923)) |
| Sep to Dec 2026 | [Foralumab topline data readout](https://sec-api.dev/pdufa/foralumab) | TLSA | Secondary Progressive Multiple Sclerosis | scheduled | "NCT06292923 (A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06292923)) |
| September 28, 2026 | [Foralumab trial start](https://sec-api.dev/pdufa/foralumab) | TLSA |  | completed | "Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390026103735/ea030682901ex99-1.htm)) |
| November 2, 2026 | [Foralumab topline data readout](https://sec-api.dev/pdufa/foralumab) | TLSA |  | completed, positive | "Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced positive topline data in its Phase 2a INFORM-MS trial with intranasal foralumab (a human, anti-CD3 monoclonal antibody) in patients with non-active secondary progressive multiple sclerosis (na-SPMS)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390026114650/ea031046501ex99-1.htm)) |
| Q1 2027 | [Foralumab topline data readout](https://sec-api.dev/pdufa/foralumab) | TLSA |  | scheduled | "Topline data are anticipated to be announced in Q1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1723069/000121390026110008/ea030884501ex99-1.htm)) |
| April 2027 | [Foralumab nasal primary completion](https://sec-api.dev/pdufa/foralumab-nasal) | TLSA | Multiple System Atrophy | scheduled | "NCT06868628 (A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-01 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868628)) |
| Apr to Jul 2027 | [Foralumab nasal topline data readout](https://sec-api.dev/pdufa/foralumab-nasal) | TLSA | Multiple System Atrophy | scheduled | "NCT06868628 (A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-01 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868628)) |
| July 2027 | [Foralumab nasal primary completion](https://sec-api.dev/pdufa/foralumab-nasal) | TLSA | ALS (Amyotrophic Lateral Sclerosis); ALS - Amyotrophic Lateral Sclerosis; ALS | scheduled | "NCT07688239 (The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07688239)) |
| Jul to Oct 2027 | [Foralumab nasal topline data readout](https://sec-api.dev/pdufa/foralumab-nasal) | TLSA | ALS (Amyotrophic Lateral Sclerosis); ALS - Amyotrophic Lateral Sclerosis; ALS | scheduled | "NCT07688239 (The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07688239)) |

## Drugs

- [Foralumab](https://sec-api.dev/pdufa/foralumab): non-active spms, non-active secondary progressive multiple sclerosis, early alzheimer's disease, Secondary Progressive Multiple Sclerosis
- [Foralumab nasal](https://sec-api.dev/pdufa/foralumab-nasal): Multiple System Atrophy, ALS (Amyotrophic Lateral Sclerosis)
- [Foralumab tzls-401 100 µg](https://sec-api.dev/pdufa/foralumab-tzls-401): Non-Active Secondary Progressive Multiple Sclerosis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tlsa/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TLSA catalysts: Tiziana Life Sciences Ltd PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tlsa/catalysts

```bibtex
@misc{secapidev_companies_tlsa_catalysts_20261116,
  title        = {TLSA catalysts: Tiziana Life Sciences Ltd PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tlsa/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tlsa_catalysts_20261116","title":"TLSA catalysts: Tiziana Life Sciences Ltd PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tlsa/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
